Results of a randomized and controlled clinical trial were recently published in Medicina (Kaunas), evaluating the use of silymarin in combination with conventional disease-modifying antirheumatic drugs (DMARDs) among people with active rheumatoid arthritis (RA). Over an 8-week trial period, 122 participants (85% women) diagnosed with RA and who were receiving conventional treatment (e.g., methotrexate, leflunomide,…